This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Edwards, M. H. Articles by Harris, E. N. Search for Related Content PubMed PubMed Citation Articles by Edwards, M. H. Articles by Harris, E. N.

(Circulation. 1997;96:4380-4384.)
© 1997 American Heart Association, Inc.

Articles

Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice

Michael H. Edwards, MD; Silvia Pierangeli, PhD; XiaoWei Liu, MD; John H. Barker, MD, PhD; Gary Anderson, PhD; ; E. Nigel Harris, MD

From the Division of Rheumatology, Department of Medicine (M.H.E.), the Department of Surgery (J.H.B.), and the Department of Physiology (G.A.), University of Louisville (Ky); and Morehouse School of Medicine (S.P., X.-W.L., E.N.H.), Atlanta, Ga.

Correspondence to Michael H. Edwards, MD, Medicine/Rheumatology, University of Louisville, Louisville, KY 40292.

Background Previous studies have demonstrated that human monoclonal and polyclonal anticardiolipin antibodies have thrombogenic properties in vivo. Using such a model in which these antibodies have been shown to increase both the size of an induced thrombus and the duration of time in which such a clot lasts, we investigated whether hydroxychloroquine alters the dynamics of such thrombus formation.

Methods and Results Three groups of nine mice were injected with purified immunoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hydroxychloroquine at various doses (100, 6, and 3 mg/kg body wt). Three control groups of mice were also studied, including mice injected with IgG-APS and then fed with placebo, as well as two other groups injected with IgG from normal human serum and fed either hydroxychloroquine or placebo. A standardized thrombogenic injury was subsequently induced in the femoral vein of each mouse and the area (size) of thrombus measured as well as the total period of time that thrombus was present. Mice treated with hydroxychloroquine and IgG-APS showed significantly smaller thrombi that persisted for a shorter period of time compared with animals treated with IgG-APS and placebo.

Conclusions Hydroxychloroquine significantly diminished both thrombus size and total time of thrombus formation in mice previously injected with IgG-APS.

Key Words: thrombus • antibodies • anticoagulants • drugs • hydroxychloroquine

This article has been cited by other articles:

				G Ruiz-Irastorza and M. Khamashta Hydroxychloroquine: the cornerstone of lupus therapy Lupus, April 1, 2008; 17(4): 271 - 273. [PDF]

				X. Feng, H. Li, A. A. Rumbin, X. Wang, A. La Cava, K. Brechtelsbauer, L. W. Castellani, J. L. Witztum, A. J. Lusis, and B. P. Tsao ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia J. Lipid Res., April 1, 2007; 48(4): 794 - 805. [Abstract] [Full Text] [PDF]

				G Ruiz-Irastorza, M-V Egurbide, J-I Pijoan, M Garmendia, I Villar, A Martinez-Berriotxoa, J-G Erdozain, and C Aguirre Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus Lupus, September 1, 2006; 15(9): 577 - 583. [Abstract] [PDF]

				M Petri Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort Lupus, December 1, 2005; 14(12): 970 - 973. [Abstract] [PDF]

				F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]

				K. T. Ho, C. W. Ahn, G. S. Alarcon, B. A. Baethge, F. K. Tan, J. Roseman, H. M. Bastian, B. J. Fessler, G. McGwin Jr, L. M. Vila, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events Rheumatology, October 1, 2005; 44(10): 1303 - 1307. [Abstract] [Full Text] [PDF]

				E Toubi, A Kessel, I Rosner, M Rozenbaum, M Lorber, D Paran, E Sabo, and T D Golan Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE Lupus, April 1, 2003; 12(4): 297 - 301. [Abstract] [PDF]

				D. Erkan, Y. Yazici, M. G. Peterson, L. Sammaritano, and M. D. Lockshin A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome Rheumatology, August 1, 2002; 41(8): 924 - 929. [Abstract] [Full Text] [PDF]

				J-C Piette, A Sbai, and C Frances Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus Lupus, February 1, 2002; 11(2): 67 - 70. [PDF]

				D D'Cruz Antimalarial therapy: a panacea for mild lupus? Lupus, March 1, 2001; 10(3): 148 - 151. [Abstract] [PDF]